Please assess the completion status of the following clinical trial:

Trial Title: A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Men and women, ages 18-75 inclusive~* Adult recipients of a renal allograft from a living donor or a deceased donor between 6-60 months prior to enrollment~* Receiving a stable (≥1 month) regimen of Calcineurin inhibitor (CNI) \[Cyclosporine A (CsA) or Tacrolimus (TAC)\] with Mycophenolate mofetil (MMF) or Enteric Coated Mycophenolate Sodium (EC-MPS)/Mycophenolic acid (MPA), and corticosteroids~* Stable renal function for 12 weeks prior to enrollment without new onset proteinuria~* Calculated glomerular filtration rate (cGFR) ≥30 and ≤75 mL/min/1.73 m2 \[Modification of Diet in Renal Disease study (MDRD) 4-formula\]~Exclusion Criteria:~* Recipients with Epstein-Barr virus (EBV) serostatus negative or unknown~* History of acute rejection (AR) within 3 months prior to enrollment~* History of antibody mediated rejection~* Positive T-cell lymphocytotoxic cross match~* Proteinuria \>1 g/day or \>0.5 g/day if diabetic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Belatacept (Type: EXPERIMENTAL): Belatacept 5 mg/kg intravenous 30 minute infusion on Days 1, 15, 29, 43, 57 then every 28 days for 24 months
- CNI (Type: ACTIVE_COMPARATOR): Tacrolimus 4-11 ng/mL tablet orally according to package insert for 24 months~Cyclosporine 50-250 ng/mL tablet orally according to package insert for 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).